Mevacor, Ditropan Switch Discussions With FDA Proceeding Well – J&J
This article was originally published in The Tan Sheet
Executive Summary
Discussions between FDA and J&J/Merck over the potential Rx-to-OTC switch of cholesterol-reducing statin Mevacor have been moving in a positive direction, J&J Consumer Pharmaceuticals & Nutritional Products Worldwide Chairman Brian Perkins reported